Ocular metastases from breast carcinoma

Intraocular metastases are the most common malignancy of the eye, and the primary cause is breast cancer. This is a retrospective analysis, which reports the clinical experience of eye metastases in 16 patients during the period of January, 1991, to December, 2002, who attended a tertiary referral c...

Full description

Saved in:
Bibliographic Details
Published in:Medical oncology (Northwood, London, England) London, England), 2004-01, Vol.21 (3), p.217-222
Main Authors: Mejía-Novelo, Alberto, Alvarado-Miranda, Alberto, Morales-Vázquez, Flavia, Gamboa-Vignole, Carlos, Núñez-Gómez, Rodrigo, Castañeda-Soto, Noel, Dueñas-González, Alfonso, Candelaria-Hernández, Myrna, Lara-Medina, Fernando
Format: Article
Language:English
Subjects:
Adult
Breast - pathology
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Eye Neoplasms - diagnosis
Eye Neoplasms - mortality
Eye Neoplasms - radiotherapy
Eye Neoplasms - secondary
Female
Follow-Up Studies
Humans
Middle Aged
Neoplasm Staging
Oncology
Prognosis
Quality of Life
Radiotherapy Dosage
Retrospective Studies
Survival Analysis
Time Factors
Visual Acuity
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intraocular metastases are the most common malignancy of the eye, and the primary cause is breast cancer. This is a retrospective analysis, which reports the clinical experience of eye metastases in 16 patients during the period of January, 1991, to December, 2002, who attended a tertiary referral center in Mexico City. Mean age at diagnosis was 40 yr (range 24-58). Most of patients were initially in clinical stage IIB-IV. Median time from breast cancer diagnosis to development of ocular metastases was 22.5 mo and from metastatic disease to ocular metastases was 10 mo. Ocular symptoms were decrease of visual acuity, ocular pain, nonspecific symptoms, proptosis, and palpebral edema. Three patients had bilateral ocular metastases. Fourteen patients were treated with radiation, and clinical response was documented in 4/15 eyes; ocular pain responded in three patients with this symptom. No ocular enucleations were performed. One patient developed glaucoma. No other major toxicities were documented. Median survival time was 26 mo and 25% of our patients were alive at a maximum follow-up of 90 mo. This entity requires early recognition in order to preserve the visual function and quality of life of patients with breast cancer, since their prognosis has improved in recent years.
ISSN:1357-0560
1357-0560
1559-131X
DOI:10.1385/MO:21:3:217